NCT00947037WithdrawnPhase 2
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Withdrawn
- Sponsor
- Intec Pharma Ltd.
- Locations
- 5
- Primary Endpoint
- To assess patient and investigator global evaluation of, and degree of satisfaction with, AP-CD/LD (CGI, GSS)
Study Overview
Brief Summary
An extension of study IN 09 004 testing the long term safety of the Accordion Pill Carbidopa/Levodopa (AP-CD/LD)
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 30 Years to 95 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject satisfactorily completed study IN 09 004 and, in the opinion of the investigator, will benefit from participation in the extension study
- •Subject with Parkinson's disease experiencing predictable motor fluctuations, end of dose "wearing off", defined by the patient's report of at least two episodes daily of a decline in function from peak benefit, with at least 2 hours OFF a day at the discretion of the PI (does not include early morning akinesia or nocturnal akinesia)
- •Subject that has been treated for at least 3 months prior to the study with 500-1000 mg Levodopa + DDCI, in 4 or more divided doses per day
- •Hoehn and Yahr stages I-III
- •Subjects must be able to adhere to the visit schedule and protocol requirements and be available to complete the study
- •Prepared and able to give written (signed and dated) informed consent, which includes compliance with study requirements and restrictions prior to admission to the study.
- •Exclusion Criteria
- •Subject has undergone Deep brain stimulation (DBS) or any other neurological surgical procedure that affects neurological symptoms (e.g tremor, rigidity, stiffness, slowed movement, and walking problem)
- •Subjects with any gastrointestinal surgery other than appendectomy or herniotomy, recent history of inflammatory bowel disease, irritable bowel syndrome, severe gastrointestinal narrowing, intestinal obstruction, or frequent nausea or emesis or diarrhea which, in the opinion of the investigator, contraindicates his/her participation
- •Subjects with a recent history of clinically defined GERD, peptic ulcer or any gastrointestinal disorder likely to influence drug absorption which, in the opinion of the investigator, contraindicates his/her participation
Exclusion Criteria
- Not provided
Arms & Interventions
Extension
Experimental
Open label extension, 1 arm
Intervention: AP-CD/LD (Drug)
Outcomes
Primary Outcomes
To assess patient and investigator global evaluation of, and degree of satisfaction with, AP-CD/LD (CGI, GSS)
Secondary Outcomes
- Daytime sleepiness
- Quality of Life questionnaires
- Efficacy measures of motor symptoms
Investigators
Study Sites (5)
Loading locations...
Similar Trials
Completed
Phase 2
An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)Thrombocythemia, EssentialPrimary MyelofibrosisNCT05223920Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)80
Completed
Phase 3
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.Bipolar I DisorderNCT00228059Novartis132
Completed
Phase 3
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I DisorderBipolar I DisorderNCT00238485Novartis251
Unknown
Phase 3
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004Parkinson's DiseaseNCT02615873Intec Pharma Ltd.460
Completed
Phase 2
A Long Term, Safety Study of Apricitabine in HIV-infected SubjectsHIV InfectionNCT00367952Avexa42